| Description | Aniracetam(Ro 13-5057) is a nootropics and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR.Target: AMPA; nAChRAniracetam is an ampakine and nootropic of the racetam chemical class purported to be considerably more potent than piracetam. It selectively modulates the AMPA receptor. It is lipid soluble and has possible cognition enhancing effects. It has been tested in animals extensively, Alzheimer's patients and temporarily-impaired healthy subjects. It has shown potential as an anxiolytic in three clinical animal models [1].Administration of aniracetam for 10 days (post-natal days (PND) 18-27), at a dose of 50 mg/kg reversed cognitive deficits in both rat genders, indicated by a significant increase in the number of avoidances and the number of 'good learners'. After the termination of the nootropic treatment, a significant increase in both amplitude and frequency of AMPA receptor-mediated mEPSCs in hippocampal CA-1 pyramidal cells was observed [2].Clinical indications: Cognitive disorder; StrokeFDA Approved Date: Toxicity: insomnia; headaches; nausea or rash. |
|---|
| Related Catalog | Signaling Pathways >> Membrane Transporter/Ion Channel >> iGluR Signaling Pathways >> Neuronal Signaling >> iGluR Signaling Pathways >> Membrane Transporter/Ion Channel >> nAChR Signaling Pathways >> Neuronal Signaling >> nAChR Research Areas >> Neurological Disease |
|---|
| Solvent | In Vitro: DMSO : ≥ 100 mg/mL (456.12 mM) H2O : 0.33 mg/mL (1.51 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown. In Vivo: 1.Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution 2.Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution 3.Add each solvent one by one: 10% DMSO 90% corn oil Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution |
|---|
| Solubility | 1 mM4.5612 mL22.8061 mL45.6121 mL5 mM0.9122 mL4.5612 mL9.1224 mL10 mM0.4561 mL2.2806 mL4.5612 mL |
|---|
| Storage | Powder-20°C3 years 4°C2 yearsIn solvent-80°C6 months -20°C1 month |
|---|
| Shipping | Room temperature in continental US; may vary elsewhere |
|---|
| SMILES | O=C(N1CCCC1=O)C2=CC=C(OC)C=C2 |
|---|
| References | [1]. Nakamura K, et al. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. [2]. Vaglenova J, et al. Aniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptors. Neuropsychopharmacology. 2008 Apr;33(5):1071-83. Epub 2007 Jul 4. |
|---|
| Related Molecules | (+)-MK 801 Maleate | PNU 282987 | CNQX | Carbachol | N-Methyl-D-aspartic acid | GTS-21 | Methyllycaconitine citrate | ifenprodil tartrate | D-AP5(mM/ml) | DNQX | Ro 25-6981 maleate | Monepantel | Flupirtine maleate | Mibampator |
|---|
China
